Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting

References

• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2017;40(Suppl 1):S1-S120
   PubMedGoogle Scholar
• National Committee for Quality Assurance (NCQA). Comprehensive diabetes care. Washington, D.C. USA. 2017. Available online at: http://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2016-table-of-contents/diabetes-care. Accessed 31 January 2018
   Google Scholar
• Janssen Pharmaceuticals Inc. Prescribing information for Invokana (canagliflozin). Titusville, NJ, USA: Janssen Pharmaceuticals Inc; 2017
   Google Scholar
• Janssen Pharmaceuticals Inc. Prescribing information for Invokamet (canagliflozin and metformin hydrochloride). Titusville, NJ, USA: Janssen Pharmaceuticals Inc; 2017
   Google Scholar
• Seufert J. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obesity: Targets Ther 2015;8:543-54
   PubMed Web of Science ®Google Scholar
• Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015;6:3-18
   PubMed Web of Science ®Google Scholar
• Buysman EK, Chow W, Henk HJ, et al. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin 2015;31:137-43
   PubMed Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obesity Metab 2014;16:467-77
   PubMed Web of Science ®Google Scholar
• Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. Diabetes Care 2011;34(Suppl 2):S279-84
   PubMed Web of Science ®Google Scholar
• Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One 2015;10:e0125879
   PubMed Web of Science ®Google Scholar
• Lorenzi M, Ploug UJ, Langer J, et al. Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis. Diabetes Ther 2017;8:85-99
   PubMed Web of Science ®Google Scholar
• Pacou M, Taieb V, Abrams KR, et al. Bayesian network meta-analysis to assess relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Value Health 2013;16:A609
   Web of Science ®Google Scholar
• Van Sanden S, Diels J, Guillon P, et al. Bayesian network meta-analysis to assess relative efficacy of canagliflozin versus glucagon-like peptide-1 receptor agonists in dual and triple therapy in patients with type 2 diabetes mellitus. 20th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 16–20, 2015; Philadelphia, PA
   Google Scholar
• United States Food and Drug Administration. FDA-approved diabetes medicines. Silver Spring, MD, USA. 2017. Available online at: https://www.fda.gov/forpatients/illness/diabetes/ucm408682.htm. Accessed August 2017
   Google Scholar
• Lefebvre P, Pilon D, Robitaille M-N, et al. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin—an electronic health-record-based study. Curr Med Res Opin 2016;32:1151-9
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res 2017;26:1654-1670
   PubMed Web of Science ®Google Scholar
• Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45(10 Suppl 2):S103-S7
   PubMed Web of Science ®Google Scholar
• Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-25
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. Toronto, ON: Academic Press Inc.; 1977
   Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simul Comput 2009;38:1228-34
   Web of Science ®Google Scholar
• Gurgle HE, White K, McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag 2016;12:239-49
   PubMed Web of Science ®Google Scholar
• Wilke T, Mueller S, Groth A, et al. Non-persistence and non-adherence of patients with type 2 diabetes mellitus in therapy with GLP-1 receptor agonists: a retrospective analysis. Diabetes Ther 2016;7:105-24
   PubMed Web of Science ®Google Scholar
• Cai J, Wang Y, Baser O, et al. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. J Med Econ 2016;19:1175-86
   PubMed Web of Science ®Google Scholar
• Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Tech Ther 2015;17:35-42
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381:117-24
   PubMed Web of Science ®Google Scholar
• Wysham CH, Pilon D, Ingham M, et al. Glycemic control and treatment costs in patients with type 2 diabetes mellitus initiated on canagliflozin 300 mg or a glucagon-like peptide-1 receptor agonist in a real-world setting. In: 77th Scientific Sessions of the American Diabetes Association; San Diego, CA; June 9-13, 2017
   Google Scholar